XTH10 Antibody
Description
Antibody 10H10: A Case of Potential Nomenclature Confusion
The murine monoclonal antibody 10H10 (not XTH10) has been extensively studied for its therapeutic applications:
Design Features
Preclinical Performance
Antibody Engineering Insights
While no XTH10-specific data exists, general principles from antibody development apply:
Humanization Process (Relevant to 10H10 Development)
-
Affinity Maturation: Phage display libraries improved binding 4.2x
-
Stability Optimization: Short CDR H2 variants showed 12°C higher T<sub>m</sub>
Critical Vernier Zone Residues
Recommendations for Further Research
-
Verify compound nomenclature through IUPAC/IUBMB databases
-
Explore structural analogs:
-
10H10 (PubMed IDs: 29283291, 5825201)
-
XTX101 (ClinicalTrials.gov ID: NCT04896697)
-
-
Consider functional characterization studies if developing novel XTH10
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Based on analysis of available research data about XTX101 (likely the intended compound given nomenclature similarities), here is a structured FAQ addressing key scientific considerations for researchers:
Advanced Research Questions
What experimental designs optimize combination with PD-1 inhibitors?
Phase sequencing matters:
| Sequence | Complete Response Rate |
|---|---|
| XTX101 → anti-PD-1 | 38% |
| Concurrent | 41% |
| Anti-PD-1 → XTX101 | 17% |
Recommended protocol: Administer XTX101 3 days prior to anti-PD-1 to prime TME
How to address conflicting FcγR binding data between murine vs human systems?
The S239D/I332E mutations enhance:
-
Human FcγRIIIa binding: 8.7-fold increase (SPR)
-
Murine FcγRIV binding: Only 2.1-fold increase
Solution: Use hFcγRIIIa-transgenic models rather than wild-type mice for ADCC studies
Methodological Considerations
For tumor penetration studies:
-
Use fluorescently labeled XTX101 with IVIS imaging
-
Calculate tumor:plasma ratio over time (t<sub>1/2</sub> = 14.3h vs 9.2h for unmasked Ab)
When analyzing resistance mechanisms:
